📊 MDT Key Takeaways
Is Medtronic plc (MDT) a Good Investment?
Medtronic demonstrates exceptional financial health with robust profitability margins (17.3% operating margin), strong free cash flow generation ($3.3B annually), and a solid balance sheet with conservative leverage (0.57x debt/equity). The company's strong liquidity position (2.54x current ratio) combined with healthy interest coverage (6.4x) indicates excellent capacity to service debt and invest in growth.
Medtronic shows solid core financial health with strong liquidity, positive free cash flow, and acceptable leverage, supported by a 17.3% operating margin and $3.34B of free cash flow. However, growth quality is mixed because net income was essentially flat, the reported 6,463.0% revenue growth appears anomalous, and the unusually low 14.1% gross margin raises questions about comparability or underlying cost pressure. Overall, the fundamentals support stability more than clear acceleration.
Why Buy Medtronic plc Stock? MDT Key Strengths
- Strong operational efficiency with 17.3% operating margin and 13.4% net margin
- Robust free cash flow of $3.3B with 12.6% FCF margin providing capital flexibility
- Conservative leverage at 0.57x debt/equity with excellent interest coverage of 6.4x
- Solid liquidity position with 2.54x current ratio and 1.87x quick ratio
- Substantial revenue base of $26.6B indicating scale and market presence
- Operating cash flow of $4.8B covering capex 3.4x over, demonstrating cash generation strength
- Strong liquidity with a 2.54x current ratio and 1.87x quick ratio
- Consistent cash generation with $4.76B operating cash flow and $3.34B free cash flow
- Moderate leverage profile with 0.57x debt/equity and 6.4x interest coverage
MDT Stock Risks: Medtronic plc Investment Risks
- Extreme revenue growth of 6463% YoY suggests data anomaly or major acquisition/accounting change requiring verification
- Concerning ROE of 7.3% and ROA of 3.9% indicate relatively low returns on deployed capital despite strong margins
- High long-term debt of $27.9B represents significant financial obligation requiring ongoing service capacity
- Declining net income (-0.6% YoY) despite massive revenue growth raises questions about underlying business momentum and cost structure
- Low cash position of $1.1B relative to $91.5B in assets suggests limited financial cushion for unexpected challenges
- Reported revenue growth appears distorted, reducing confidence in underlying growth quality
- Net income declined 0.6% YoY, suggesting earnings growth is not broad-based
- Low gross margin relative to operating margin may indicate cost pressure or data classification issues
Key Metrics to Watch
- Organic revenue growth rate (excluding acquisition impact) to validate underlying business growth
- Trend in ROE and ROA to assess capital deployment efficiency improvements
- Net income growth trajectory to confirm profitability sustainability
- Free cash flow consistency and conversion rate from operating cash flow
- Debt reduction progress and leverage ratio trajectory
- Operating margin sustainability amid potential cost inflation
- Organic revenue growth and revenue consistency across future filings
- Gross margin and free cash flow conversion
Medtronic plc (MDT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.54x current ratio provides a solid financial cushion.
MDT Profit Margin, ROE & Profitability Analysis
MDT vs Healthcare Sector: How Medtronic plc Compares
How Medtronic plc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Medtronic plc Stock Overvalued? MDT Valuation Analysis 2026
Based on fundamental analysis, Medtronic plc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Medtronic plc Balance Sheet: MDT Debt, Cash & Liquidity
MDT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Medtronic plc's revenue has shown modest growth of 10% over the 5-year period. The most recent EPS of $2.82 reflects profitable operations.
MDT Revenue Growth, EPS Growth & YoY Performance
MDT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $8.3B | $1.1B | $0.89 |
| Q2 2026 | $8.4B | $1.3B | $0.99 |
| Q1 2026 | $7.9B | $1.0B | $0.80 |
| Q3 2025 | $8.1B | $1.3B | $0.99 |
| Q2 2025 | $8.0B | $909.0M | $0.68 |
| Q1 2025 | $7.7B | $791.0M | $0.59 |
| Q3 2024 | $7.7B | $1.2B | $0.92 |
| Q2 2024 | $7.6B | $427.0M | $0.32 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Medtronic plc Dividends, Buybacks & Capital Allocation
MDT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Medtronic plc (CIK: 0001613103)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MDT
What is the AI rating for MDT?
Medtronic plc (MDT) has a Combined AI Rating of BUY from Claude (STRONG BUY) and ChatGPT (HOLD) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MDT's key strengths?
Claude: Strong operational efficiency with 17.3% operating margin and 13.4% net margin. Robust free cash flow of $3.3B with 12.6% FCF margin providing capital flexibility. ChatGPT: Strong liquidity with a 2.54x current ratio and 1.87x quick ratio. Consistent cash generation with $4.76B operating cash flow and $3.34B free cash flow.
What are the risks of investing in MDT?
Claude: Extreme revenue growth of 6463% YoY suggests data anomaly or major acquisition/accounting change requiring verification. Concerning ROE of 7.3% and ROA of 3.9% indicate relatively low returns on deployed capital despite strong margins. ChatGPT: Reported revenue growth appears distorted, reducing confidence in underlying growth quality. Net income declined 0.6% YoY, suggesting earnings growth is not broad-based.
What is MDT's revenue and growth?
Medtronic plc reported revenue of $26.6B.
Does MDT pay dividends?
Medtronic plc pays dividends, with $2,731.0M distributed to shareholders in the trailing twelve months.
Where can I find MDT SEC filings?
Official SEC filings for Medtronic plc (CIK: 0001613103) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MDT's EPS?
Medtronic plc has a diluted EPS of $2.76.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MDT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Medtronic plc has a BUY rating with 80% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is MDT stock overvalued or undervalued?
Valuation metrics for MDT: ROE of 7.3% (sector avg: 15%), net margin of 13.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MDT stock in 2026?
Our dual AI analysis gives Medtronic plc a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is MDT's free cash flow?
Medtronic plc's operating cash flow is $4.8B, with capital expenditures of $1.4B. FCF margin is 12.6%.
How does MDT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 13.4% (avg: 12%), ROE 7.3% (avg: 15%), current ratio 2.54 (avg: 2).